iMmuNeo is a cancer immunotherapy company that is developing personalized cancer vaccines. We aim to be the world's leading personalized cancer vaccine company, impacting the treatment of major human cancers including those of the ovaries, lungs, pancreas, breast, prostate, colorectal tissues, stomach and skin.
Immunology, genomics, bioinformatics and cancer clinical trials are our core strengths.
In light of the extraordinary public interest in preventive health, partly as a result of COVID19, iMmuNeo shall offer a subscription service where, after filling out a detailed questionnaire, subscribers may receive personalized guidance to enhance their immunity and improve their health and well-being. This subscription service shall be available, starting in the 3rd quarter of 2020. Depending upon an individual subscriber’s interest, multiple levels of this service shall be available.